Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic UD NK and TGFBi NK cells
- Development stage
- Unknown
- Lead developer
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral, Intralesional
01
Overview
This investigational cell therapy involves the intralesional injection of ex-vivo expanded allogeneic natural killer (NK) cells. Developed at the University of Minnesota and led by investigator Kirsten Johnson, the therapy is being evaluated in an early phase I clinical trial for cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). The study compares standard universal donor (UD) NK cells with TGF-beta-imprinted (TGFBi) NK cells. TGFBi NK cells are a unique population of 'adaptive' NK cells derived from cytomegalovirus (CMV)-exposed donors and treated with TGF-beta during expansion. This imprinting process is designed to enhance the cells' anti-tumor potency, persistence, and metabolic fitness within the immunosuppressive tumor microenvironment. The cells are administered via direct intratumoral injection prior to standard-of-care surgical excision to assess safety and biological activity.
- Other names
- Universal Donor Expanded NK CellsTGF-beta-imprinted NK CellsEx-Vivo Expanded Allogenic University Donor NK Cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on Allogeneic UD NK and TGFBi NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic UD NK and TGFBi NK cells.